Welcome to our dedicated page for Bayer Aktien news (Ticker: BAYRY), a resource for investors and traders seeking the latest updates and insights on Bayer Aktien stock.
BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer has appointed William Dodero as the new U.S. General Counsel effective January 1, 2023. He succeeds Scott Partridge, who is leaving to focus on dispute resolution. Dodero brings 20 years of experience with Bayer and has successfully led the company's legal strategies in various areas, including the Roundup litigation. He will oversee compliance, corporate law, and other legal functions. Patrick Lockwood-Taylor, President of Bayer U.S., expressed enthusiasm about Dodero's leadership amid growing challenges in food security and healthcare.
Prime Medicine has appointed Wendy Chung, Kaye Foster, and Michael A. Kelly to its board of directors. These new members bring extensive experience in research and development, financial management, and human resources, enhancing the company’s leadership. CEO Keith Gottesdiener emphasized the importance of a strong team to advance their novel Prime Editing technology, which aims to provide one-time curative genetic therapies for a wide range of diseases. This appointment is expected to support the company’s goal of delivering potentially life-changing treatments.
The Fears Nachawati law firm is urging a federal judge to reject a proposed settlement between Bayer (OTCMKTS: BAYZF, BAYRY) and consumers seeking reimbursement for Roundup. They allege that the settlement could limit cancer victims' ability to seek justice. Representing over 4,000 cancer victims, the firm raises concerns about collusion due to generous legal fees and ambiguous language that may protect Monsanto from damages. Previous attempts at a similar settlement were blocked by the JPML. Notably, several trials have found that Roundup exposure causes cancer, leading to multimillion-dollar verdicts.
A panel has denied Bayer's request to settle lawsuits linked to its Roundup herbicide, impacting ongoing multidistrict litigation affecting thousands of cancer victims. The Judicial Panel on Multidistrict Litigation ruled on Oct. 8, transferring the case to U.S. District Judge Vince Chhabria, who has previously rejected settlements from Monsanto. Legal representatives criticized Bayer's actions as an attempt to limit justice for cancer victims, emphasizing the judge's capability to handle such cases. Three prior bellwether trials have ruled against Bayer, affirming that Roundup exposure caused cancer.
Bayer's impact investment arm, Leaps by Bayer, has co-led a USD 15 million Series A investment in Andes, an innovator in seed treatment technology. This investment aims to advance Andes' 'Microprime' technology, which reduces reliance on synthetic fertilizers by enhancing nitrogen fixation from the air. The initial Microprime corn seeds provide 30 to 50 lbs/acre of nitrogen. Additionally, Andes is developing carbon capture solutions to sequester CO2, targeting gigatons of annual emissions reduction. The funding supports scaling these eco-friendly innovations in the U.S. and South America.
Summary not available.
Innovative Partnerships Group (IPG) has launched a new division, IPG Health, aimed at enhancing corporate partnerships in the healthcare and life sciences sectors. This division will be led by Eric Marton, a seasoned expert with over 25 years in healthcare and venture capital. Marton will drive growth and expand IPG's technology portfolio, working with clients including Bayer (BAYRY), eHealth (EHTH), and Herbalife (HLF). IPG Health focuses on creating innovative financing solutions and transforming vendor relationships into sustainable partnerships.
Fears Nachawati Law Firm celebrates a significant ruling from U.S. District Judge Vince Chhabria that rejected Bayer AG's proposed settlement concerning Roundup cancer claims. Judge Chhabria criticized the settlement for being unfair and limiting future lawsuits from cancer victims exposed to Roundup, developed by Monsanto, acquired by Bayer in 2018. This ruling allows over 4,000 current and future cancer victims to pursue individual trials, holding Bayer accountable for potential damages related to non-Hodgkin lymphoma cases. The multidistrict litigation continues in California's federal court.
On May 19, 2021, lawyers for cancer victims urged a federal judge to reject a settlement proposal that would enable Bayer AG to continue selling Roundup while limiting future legal claims for non-Hodgkins lymphoma diagnoses. The proposal, criticized during a hearing by U.S. District Judge Vince Chhabria, would require exposed individuals to forfeit rights to sue if diagnosed later. Trial lawyers represent over 4,000 affected individuals and remain hopeful that the court will deny Bayer's request. A ruling on the settlement is expected later.
A federal appellate court's ruling upheld findings that Bayer AG's Monsanto Roundup caused a California man's non-Hodgkins lymphoma, impacting Bayer's efforts to finalize a settlement for over 90,000 pending cancer lawsuits. The ruling confirms the causal link between Roundup and cancer, with previous jury awards totaling $5 million in compensatory damages and $75 million in punitive damages, later reduced to $20 million. Critics argue the proposed settlement limits future legal options for cancer victims. A hearing on the settlement is scheduled for May 19.
FAQ
What is the current stock price of Bayer Aktien (BAYRY)?
What is the market cap of Bayer Aktien (BAYRY)?
